Mirum Pharmaceuticals and Incyte said positive pivotal Phase 2 data from Cohort 1 of the PROGRESS study, lifting investor attention on zilurgisertib, an investigational oral treatment for fibrodysplasia ossificans progressiva (FOP). The results—reported in a presentation at the Endocrine Society’s annual meeting, ENDO 2026—showed fewer new heterotopic ossification lesions versus placebo at week 24, a key readout for the program.
FOP is an ultra-rare genetic disorder in which skeletal muscle and connective tissue gradually transform into bone. Mirum estimates the condition affects about 300 patients in the United States and roughly 900 patients worldwide, with diagnoses typically occurring in early childhood.
Key takeaways
- Price move: Mirum Pharmaceuticals shares closed at $99.35 on Dec. 6, 2026, down 0.20%.
- Catalyst: Positive Cohort 1 Phase 2 results for zilurgisertib were presented at ENDO 2026.
- Primary endpoint: At week 24, the proportion of patients with new heterotopic ossification lesions on whole-body CT improved versus placebo.
- Magnitude of effect: Mirum reported an 81% reduction in patients with new lesions versus placebo and a 99.9% reduction in the total volume of new lesions.
- Implication: The program continues to advance toward a potential FDA decision on its NDA planned for September 2026.
What drove the move
The near-term market reaction appears tied to the reported strength of the imaging-based efficacy signals in PROGRESS Cohort 1. The study is designed to evaluate whether zilurgisertib can reduce new heterotopic ossification (HO), the abnormal formation of bone in muscles, tendons, ligaments, and other soft tissues that defines FOP.
Zilurgisertib is an ALK2/ACVR1 inhibitor. In FOP, mutant ALK2 signaling is abnormally activated, driving heterotopic ossification. By targeting that pathway, the trial aims to limit the emergence and growth of new lesions and to slow disease activity as measured on whole-body CT scans.
According to Mirum, the Cohort 1 primary endpoint—new HO lesions on whole-body CT at week 24—showed fewer treated patients developing new lesions compared with placebo. The company also highlighted a pronounced reduction in the total volume of new lesions, which investors typically view as an indicator that treatment may affect both the incidence and extent of new disease activity.
Trial results and what they suggest
PROGRESS is a global, randomized, double-blind, placebo-controlled Phase 2 study evaluating efficacy and safety of zilurgisertib. Cohort 1 enrolled adolescents and adults aged 12 and older and randomized participants 1:1 to zilurgisertib 100 mg once daily or placebo during a 24-week double-blind period, followed by an open-label extension.
Mirum said that, among patients treated with zilurgisertib, fewer individuals developed new HO lesions at week 24, representing an 81% reduction versus placebo. The company further reported a 99.9% reduction in the total volume of new HO lesions for patients receiving zilurgisertib versus placebo at week 24.
Mirum also described durability and extension observations through week 48. In patients who received zilurgisertib, the company said no new HO lesions were observed and total HO lesion volume continued to decrease from week 24 to week 48. For patients who crossed over to placebo, Mirum reported no new lesions and a decrease in total HO lesion volume from week 24 to week 48.
The company added that zilurgisertib was generally well tolerated during the placebo-controlled 24-week portion of the trial, an important consideration as investors weigh the balance between efficacy and tolerability in chronic conditions.
Regulatory and commercial context
Mirum said it obtained exclusive worldwide rights from Incyte in 2026 for zilurgisertib. The asset is currently awaiting an FDA decision on its NDA for FOP, scheduled for September 2026.
For investors, the reported data matter not only for clinical confidence but also for how they may inform the NDA review timeline. With an FDA decision approaching in roughly the same timeframe as the company’s reported trial milestones, investors will likely focus on whether additional cohorts, endpoints, and safety details—along with regulatory discussions—support the strength of the Cohort 1 signals.
Mirum’s stock has experienced wide trading ranges over the past year, reflecting the high sensitivity of biotech shares to clinical updates and regulatory expectations.
What to watch next
Investors will likely watch for further disclosures tied to the PROGRESS program, including additional cohort data and the full presentation details supporting the week 24 and week 48 findings. With the FDA decision on the NDA slated for September 2026, attention will also turn to regulatory progress and any additional milestones that could influence the filing’s risk profile and expectations ahead of review.
